Skip to Content
Merck
All Photos(1)

Key Documents

59356-U

Supelco

Discovery® Cyano (5 µm) HPLC Columns

L × I.D. 15 cm × 4.6 mm, HPLC Column

Synonym(s):

Cyano Bonded Phase Column

Sign Into View Organizational & Contract Pricing


About This Item

UNSPSC Code:
41115700
eCl@ss:
32110501
NACRES:
SB.52

product name

Discovery® Cyano HPLC Column, 5 μm particle size, L × I.D. 15 cm × 4.6 mm

material

stainless steel column

Quality Level

Agency

suitable for USP L10

product line

Discovery®

feature

endcapped

manufacturer/tradename

Discovery®

packaging

1 ea of

extent of labeling

4.5% Carbon loading

parameter

≤70 °C temp. range
400 bar pressure (5801 psi)

technique(s)

HPLC: suitable
LC/MS: suitable

L × I.D.

15 cm × 4.6 mm

surface area

200 m2/g

surface coverage

3.5 μmol/m2

impurities

<10 ppm metals

matrix

silica gel, high purity, spherical base material
fully porous particle

matrix active group

cyano phase

particle size

5 μm

pore size

180 Å

operating pH range

2-8

application(s)

food and beverages

separation technique

hydrophilic interaction (HILIC)
normal phase
reversed phase

Looking for similar products? Visit Product Comparison Guide

General description

Discovery® Cyano HPLC column is used for the retention and separation of strongly basic analytes including quaternary ammonium salts, with excellent peak shapes.

Features and Benefits

  • Low hydrophobicity for rapid elution of hydrophobic analytes
  • Excellent peak shape and retention of strongly basic analytes
  • Retention of polar analytes
  • Unique selectivity
  • Significantly less retention than C18 (typically requires lower % organic mobile phase)
  • Stable, low-bleed LC-MS separations
  • Compatible with highly aqueous organic phases

Legal Information

Discovery is a registered trademark of Merck KGaA, Darmstadt, Germany

Storage Class Code

13 - Non Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Customers Also Viewed

Slide 1 of 1

1 of 1

E F Nemeth et al.
The Journal of pharmacology and experimental therapeutics, 299(1), 323-331 (2001-09-19)
Despite the discovery of many ions and molecules that activate the Ca2+ receptor, there are no known ligands that block this receptor. Reported here are the pharmacodynamic properties of a small molecule, NPS 2143, which acts as an antagonist at
S L Able et al.
British journal of pharmacology, 162(2), 405-414 (2010-09-16)
The P2X7 receptor is implicated in inflammation and pain and is therefore a potential target for therapeutic intervention. Here, the development of a native tissue radioligand binding, localization and ex vivo occupancy assay for centrally penetrant P2X7 receptor antagonists is
Thomas J Woltering et al.
Bioorganic & medicinal chemistry letters, 18(3), 1091-1095 (2007-12-22)
A series of 1,3-dihydro-benzo[b][1,4]diazepin-2-one derivatives was evaluated as non-competitive mGluR2/3 antagonists. Replacement of a cyano group by a five-membered heterocycle produced compounds inhibiting the binding of [(3)H]-LY354740 to rat mGluR2 with low nanomolar affinity and consistent functional effect at both
Fan Zhang et al.
European journal of medicinal chemistry, 46(7), 3149-3157 (2011-04-26)
A series of novel 2-amino-3-cyano-6-(1H-indol-3-yl)-4-phenylpyridine derivatives were synthesized and their cytotoxic activity against A549, H460, HT-29 and SMMC-7721 cell lines was evaluated in vitro. Among them, ten compounds (10, 11, 14, 16, 17, 26, 27, 29, 30 and 31) displayed
Graciela B Arhancet et al.
Journal of medicinal chemistry, 53(16), 5970-5978 (2010-08-03)
A new 1,4-dihydropyridine 5a, containing a cyano group at the C3 position, was recently reported to possess excellent mineralocorticoid receptor (MR) antagonist in vitro potency and no calcium channel-blocker (CCB) activity. In the present study, we report the structure-activity relationships

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service